Lucerne Fall Risk Prediction Score for Stroke Rehabilitation
Condition: Stroke Intervention: Behavioral: Standard inpatient stroke rehabilitation Sponsor: Luzerner Kantonsspital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 26, 2021 Category: Research Source Type: clinical trials
Genentech ’s Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular Degeneration
South San Francisco, CA -- January 24, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 24, 2021 Category: Pharmaceuticals Source Type: clinical trials
Effectiveness of an App Intervention to Reduce Postsurgical Symptom Distress in Patients With Vulvar Neoplasia
Condition: Vulvar Neoplasm Interventions: Other: WOMAN-PRO III; Other: Three counselling sessions with gynaecology-oncology nurses Sponsors: St.Gallen University of Applied Sciences; Cantonal Hospital of St. Gallen; Cantonal Hospital of Lucerne; Regional Hospital of Lugano; University Hospital Inselspital, Berne Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 9, 2020 Category: Research Source Type: clinical trials
